Published online Dec 18, 2015. doi: 10.4254/wjh.v7.i29.2920
Peer-review started: June 2, 2015
First decision: August 22, 2015
Revised: September 4, 2015
Accepted: November 23, 2015
Article in press: November 25, 2015
Published online: December 18, 2015
Core tip: This study on thrombophilia in 1079 patients with liver cirrhosis showed that PAI-1 4G-4G and MTHFR C677TT were statistically more frequent in 350 patients with no viral liver cirrhosis vs 729 patients with viral liver cirrhosis. In the same patients, PAI-1 and MTHFR 677 genotypes deviated from that expected from a population in the Hardy-Weinberg equilibrium. PAI-1 4G-4G and MTHFR 677TT could be considered as factors increasing the inflammation response mechanisms, causing fibrogenesis and augmented intrahepatic vascular resistance, typical of liver cirrhosis. New drug therapies based on the attenuation of these mechanisms could be very easily evaluated in these patients.